Snake Venom Components as Emerging Therapeutic Agents for Cardiovascular Diseases

Of over 4,000 snake species globally, around 600 (15-17%) are venomous, and approximately 200 of these are medically significant, posing both public health risks.Snakes, belonging to the Phylum Chordata and Class Reptilia, are among the most evolutionarily adaptable and biologically diverse vertebrates.Venomous snakes possess specialised salivary glands that produce and store venom, a complex mixture of biologically active proteins, polypeptides, and non-protein components.This review explores the therapeutic potential of snake venom components in addressing cardiovascular diseases.These venom components exhibit dominant bioactivities such as neurotoxicity, haemotoxicity, and cytotoxicity, which disrupt fundamental physiological systems in envenomed Review Articlevictims.If left untreated, snake envenomation can lead to severe morbidity or death.Snake envenomation is a significant global health challenge, with an estimated 4.5-5.4 million bites annually, resulting in tens of thousands of fatalities and numerous cases of chronic disabilities due to tissue damage and systemic complications.Despite this, snake venoms have garnered increasing attention for their therapeutic potential.Their biologically active toxin mixtures exhibit diverse pharmacological properties, making them valuable in drug discovery and development.The success of captopril, the first drug derived from the bradykinin-potentiating peptide of Bothrops jararaca venom, highlights the potential of snake venom components as lead compounds for novel therapeutic agents.Significant progress has been made in developing drugs targeting cardiovascular diseases, including treatments for coagulopathies, hemostasis, and stroke prevention.It focuses on the mechanisms through which these components influence blood pressure regulation and clotting pathways, underscoring their importance in the continuous search for innovative medical treatments.Future venom research should prioritise the exploration of unstudied snake species to uncover novel bioactive compounds for drug development and diagnostic applications.Advances in ultrasensitive analytical techniques are essential to investigate components present in minute quantities, which may hold significant therapeutic potential.

Authors

Institutions

Publication Details

Published
2025-08-04
DOI
https://doi.org/10.9734/ajrcd/2025/v7i1129
Primary Topic
Venomous Animal Envenomation and Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Snake Venom Components as Emerging Therapeutic Agents for Cardiovascular Diseases

Aliyu Ibrahim Kankara, Aliyu MUHAMMAD Lawal, Muhammad Shafi’u Abdulrauf
Venomous Animal Envenomation and Studies
article

Snake Venom Components as Emerging Therapeutic Agents for Cardiovascular Diseases

Aliyu Ibrahim Kankara, Aliyu MUHAMMAD Lawal, Muhammad Shafi’u Abdulrauf
article en

Abstract

Of over 4,000 snake species globally, around 600 (15-17%) are venomous, and approximately 200 of these are medically significant, posing both public health risks.Snakes, belonging to the Phylum Chordata and Class Reptilia, are among the most evolutionarily adaptable and biologically diverse vertebrates.Venomous snakes possess specialised salivary glands that produce and store venom, a complex mixture of biologically active proteins, polypeptides, and non-protein components.This review explores the therapeutic potential of snake venom components in addressing cardiovascular diseases.These venom components exhibit dominant bioactivities such as neurotoxicity, haemotoxicity, and cytotoxicity, which disrupt fundamental physiological systems in envenomed Review Articlevictims.If left untreated, snake envenomation can lead to severe morbidity or death.Snake envenomation is a significant global health challenge, with an estimated 4.5-5.4 million bites annually, resulting in tens of thousands of fatalities and numerous cases of chronic disabilities due to tissue damage and systemic complications.Despite this, snake venoms have garnered increasing attention for their therapeutic potential.Their biologically active toxin mixtures exhibit diverse pharmacological properties, making them valuable in drug discovery and development.The success of captopril, the first drug derived from the bradykinin-potentiating peptide of Bothrops jararaca venom, highlights the potential of snake venom components as lead compounds for novel therapeutic agents.Significant progress has been made in developing drugs targeting cardiovascular diseases, including treatments for coagulopathies, hemostasis, and stroke prevention.It focuses on the mechanisms through which these components influence blood pressure regulation and clotting pathways, underscoring their importance in the continuous search for innovative medical treatments.Future venom research should prioritise the exploration of unstudied snake species to uncover novel bioactive compounds for drug development and diagnostic applications.Advances in ultrasensitive analytical techniques are essential to investigate components present in minute quantities, which may hold significant therapeutic potential.

Vol. 7(1)
Federal University Birnin Kebbi (NG), The Federal Polytechnic, Ado-Ekiti (NG)
Openalex Percentile: Top 78%
Venomous Animal Envenomation and Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.